Automated
Scalable
Accessible
Automated
Scalable
Accessible
Limula offers a unique technology supporting routine manufacturing of highly-personalised cell therapies. We address one of the biggest challenges in this industry - How to enable the transition from open and manual methods towards closed and automated processes?
About Limula
Swiss Made engineering meets cell therapy
Our company is based in Lausanne, Switzerland. We thrive in this world-class ecosystem, tapping into the country’s long tradition of Pharma and Biotech. We have privileged access to exceptional engineering and life science talent and infrastructure, delivering the highest product quality.
Our team
We think out of the box.
We combine decades of experience in different industries to develop a highly innovative and multidisciplinary approach to Cell & Gene Therapy manufacturing.
Founders
LUC HENRY
CEO
Luc graduated from the University of Oxford with a DPhil in Chemical Biology. He has 10 years of research experience and published over 15 peer-reviewed scientific reports in chemistry, biotechnology and immunology. Prior to founding Limula, he was a strategic advisor to the President of EPFL, Martin Vetterli. At Limula, his role is to build meaningful partnerships to maximise the impact of our technology.
Yann Pierson
CTO
Yann graduated from EPFL with a PhD in Chemical Biology and is a certified mechanical designer. He invented, patented and built the first prototype of the technology behind our revolutionary CGT manufacturing platform in his garage during the COVID pandemic lock-down. At Limula, his role is to build an innovative product that meets the performance, quality and regulatory needs of our customers.
Thomas Eaton
CFO
Tom graduated from the University of Basel with a PhD in Material Sciences. Tom has extensive experience in project management, budget tracking, outsourcing and supplier oversight. He has worked for, and consulted to, multinationals, including Deloitte, UBS and SwissRe as a project facilitator. At Limula, his role is to establish company processes to support our objectives and reach our potential.
Team
Olivier Waridel
Head of Operations
Olivier was the CEO of Biosafe Group SA until the trade sale to GE Healthcare in 2016 (now part of Cytiva). Under his leadership, the Sepax device became an industry standard for cell processing in biobanks, transplantation centres, hospitals and biopharma. Before joining Limula, he was a consultant for start-up/mid-size life science tools and medical device companies.
Caroline Boudousquié
Head of Solutions
Caroline graduated from the University of Lausanne with a PhD in Immunology. She then held several academic and industry positions in onco-immunology before joining the Center for Experimental Therapeutics of the CHUV in 2026. She built and led the Process Development team with the mission to transfer cell therapy manufacturing processes from R&D to GMP production.
Shady Gawad
Head of Digital
Shady earned his PhD in biosensors and microelectronics from EPFL. He is a pioneer in the development of impedance-based sensing technologies for applications in cell biology and immunology. He previously was a Sensor Architect at Léman Micro Devices and a Sensor Designer at Measurement Specialties, Inc (now TE Connectivity).
Maria Elena GRISOSTOLO
Head of Quality
Maria Elena has a decade of experience in medtech companies including Johnson&Johnson, Medtronic and Lunaphore. As VP of Operations at Lunaphore, she played a critical role in the implementation and execution of quality and regulatory affairs, from the company inception to a successful exit.
FABIEN JAMMES
Product Lead
Fabien holds a PhD in Bioengineering from EPFL, where he specialized in microfluidics single-cell analysis applied to adoptive cell therapy. In his previous role, he made a significant contribution in the development of Cytiva’s Sefia Expansion platform for automated CAR-T manufacturing.
Jean-Baptiste Bureau
Industrialization Lead
Jean-Baptiste earned a PhD in Micro-Engineering from Université de Lille, France. He developed cell culture devices in an academic setting before specializing in life science tools industrialization at Lunaphore, managing production lines for devices and consumables.
Emilie Nallet
Senior Laboratory Technician
Emilie earned a BSc in Biomedical Diagnostics and Medical Research from the Catholic University of Lyon, France. With 14 years of R&D experience, she specializes in biological in vitro assays and laboratory management.
Philippe Mazouer
Senior Software Engineer
Philippe started his career at Philips Healthcare in the Netherlands, developing applications for X-Ray and Ultrasound systems. He was then active in the field of cell and gene therapies with Cytiva.
Sarah de la Mota
Business Development Specialist
Sarah holds an MSc in the Manufacturing and Commercialisation of Cell and Gene Therapies from University College London, UK, equipping her with both scientific and market foundations in advanced therapies.
Luca Bellosta
Product Specialist
Luca graduated with a MSc in Bioengineering at Politecnico di Milano, Italy. He gained research experience in immuno-engineering at EPFL, Switzerland.
William Bovy
Product Engineer
William holds a BSc in Mechatronics and an MSc in Biomedical Engineering. At Debiotech, he gained R&D expertise in medical devices, including a home peritoneal dialysis machine, and FDA verification.
Sarah DELLAC
Field Application Scientist
Sarah earned a PhD in Immunology and Cancer Research from Tel Aviv University, Israel. She gained experience in CAR-T production at the Sheba Medical Center, Israel, and process development at Galapagos, Netherlands.
Omran El Rifaï
Mechanical Engineer
Omran brings expertise in designing medical devices and laboratory automation systems. He began his carrier at Lambda Health System, a Swiss start-up active in robotic-based rehabilitation of the lower limbs.
Laeticia Dutoit
Application Scientist
Laeticia has a BSc in Biotechnology from HES-SO Valais. At the Lausanne hospital, she specialized in developing and transferring cell therapy processes from R&D to GMP production.
Léo Corsini
Mechatronics Engineer
Léo graduated from HEIG-VD with a BSc degree in Mechatronics, where he developed a well-rounded technical skill and bridged the gap between hardware and software.
Daniel SUDRIA LOPEZ
Quality Specialist
Daniel earned a PhD in Neurosciences from the University of Lausanne, specializing in human cell model generation. He later expanded his expertise at EPFL’s Bioengineering and Organoid Platform.
Malek Fakhouri
Hardware Technician
Malek is currently in his final year of his vocational training at the CPNV where he specialises in automation and precision engineering.
Strategic Advisory Board
Prof. Denis Migliorini
Denis is a practicing physician and Head of Neuro-oncology at the Department of Oncology of the University Hospital of Geneva (HUG), Switzerland. He also leads the Brain Tumour and Immune Cell Engineering Group at the AGORA Cancer Research Center in Lausanne. His research is focused on addressing the most important limitations of CAR T-cell therapy, including specificity, potency and manufacturing hurdles.
Prof. Bernhard Gentner
Bernhard is an associate professor of Immuno-Oncology at the Department of Oncology of the University of Lausanne Hospital (CHUV). He is attending physician and haematologist, specialist in haematologic stem cell transplantation and haematopoietic stem cell engineering. He is a group leader at the Translational stem cell and leukaemia unit of Ospedale San Raffaele in Milan, Italy. Bernhard is also a scientific co-founder of Genenta Science, a Nasdaq-listed company focusing on the development of cell-based cancer immunotherapy.
Dr. Jonathan Esensten
Jonathan is a physician-scientist who serves the director of the Advanced Biotherapy Center at Sheba Medical Center, Israel. His specialty is cellular therapy product development, manufacturing, and clinical trials. He has led cellular therapy development and manufacturing projects with academic partners, major pharma, and small biotechs. He trained in cellular immunology, clinical pathology, and transfusion medicine at the University of California, San Francisco (UCSF). He served on the faculty of the Department of Laboratory Medicine at UCSF from 2017-2023.
Dirk Groenewegen
Dirk is the founder, former CEO and Board Director of Glycostem Therapeutics, a Dutch company pioneering the development of NK and CAR-NK cell therapies for oncology applications. He is a Cell & Gene Therapy consultant and a business development expert supporting Life Science start-ups and early-stage companies.
Board of Directors
Pierre Morgon
Independent Chairman
Pierre is a seasoned board director. He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA, as an alumnus of INSEAD and IMD. Pierre has over 35 years of experience in the global pharmaceutical and biological industry with direct experience of blockbuster products in diverse markets (primary care, specialty care, hospital, vaccines, and biotechnology).
Inaki Berenguer
LifeX Ventures
Inaki is Managing Partner at LifeX Ventures, a $100M fund investing at the intersection of AI and Science. He was cofounder and CEO of CoverWallet, a tech startup reinventing insurance for small businesses that was acquired by Aon in 2020. Inaki completed his PhD degrees in Engineering at Cambridge University, an MBA at MIT, was a postdoctoral research fellow of the Cambridge-MIT Institute, and spent 2 years as a Fulbright Scholar at Columbia University.
LUC HENRY
Founder and CEO
Luc graduated from the University of Oxford with a DPhil in Chemical Biology. He has 10 years of research experience and published over 15 peer-reviewed scientific reports in chemistry, biotechnology and immunology. Prior to founding Limula, he was a strategic advisor to the President of EPFL, Martin Vetterli. At Limula, his role is to build meaningful partnerships to maximise the impact of our technology.
Thomas Eaton
Founder and COO